New treatment options for advanced, hard-to-treat cancers
Developmental Therapeutics
This program develops and tries new drug treatments and combinations to help people with advanced or treatment-resistant cancers, focusing on patients in the Case Comprehensive Cancer Center area.
Quick facts
| Grant type | P30 center grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11373560 on NIH RePORTER |
What this research studies
At Case Western Reserve, doctors and scientists work together to move promising lab discoveries into early human testing and proof-of-concept trials. The program partners with other NCI centers and industry to develop new anti-cancer agents and combinations. Major efforts include noncytotoxic epigenetic therapies and tools to predict or overcome drug resistance and treatment-related toxicity. Many projects are run as Phase I and Phase II clinical trials aimed at patients with poor-prognosis or refractory cancers.
Who could benefit from this research
Good fit: People with advanced, refractory, or poor-prognosis cancers—especially patients treated at or near the Case Comprehensive Cancer Center—are the most likely candidates for the early-phase trials.
Not a fit: Patients with early-stage cancers, benign conditions, or those who cannot travel to Cleveland are less likely to benefit directly from these clinical activities.
Why it matters
Potential benefit: If successful, this program could provide new treatment options and better outcomes for people with advanced or treatment-resistant cancers.
How similar studies have performed: Some related early-phase programs and epigenetic drugs (for example azacitidine in blood cancers) have shown benefit, but many approaches in this program are novel and remain under clinical testing.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Letterio, John James — Case Western Reserve University
- Study coordinator: Letterio, John James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.